INMB - CONSENSUS CO - INmune Bio, Inc.

This daily price chart for INmune Bio, Inc. (INMB) reflects the asset's dynamics, with a value of 7.01. The US biotech firm is betting on innovative immune correction to combat Alzheimer's. Despite the risk of trial failures and the need for R&D capital, the company relies on a modern laboratory base and the readiness of partners for mass drug production.

This indicator represents the aggregated average target price from leading investment banks, reflecting the asset's fundamental growth potential under current macroeconomic conditions. Analyzing the market's average target price on the GURU.Markets platform allows for an assessment of expert expectations regarding the success of XPro1595 trials and the prospects for combating neuroinflammation, which is critical for valuing the INmune Bio, Inc. (INMB) biotech pipeline.